Zhao Hai-Lei, Zhao Ai-Guang, You Sheng-Fu, Gu Ying, Tang Lai-Di, Yang Jin-Kun
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Zhong Xi Yi Jie He Xue Bao. 2005 Sep;3(5):378-81. doi: 10.3736/jcim20050512.
To evaluate the growth-inhibiting and anti-metastasis effects of Weichang'an Decoction (WCAD) on orthotopic transplant nude mouse model of human gastric cancer.
Forty-one nude mice were implanted with SGC-7901 cells at orthotopic site, whereas 25 were implanted with SGC-7901 cells subcutaneously. Then the nude mice in each transplantation model were divided into the same three groups which were WCAD-treated group with WCAD 0.5 ml/d taken orally, 5-FU-treated group with 5-FU 50 mg/kg intraperitoneally injected weekly and untreated control group with physiological saline 0.5 ml/d taken orally. The growth-inhibiting rates of transplant tumors were detected and the metastatic lesions were examined in the orthotopic transplant mouse model while PCNA-positive rate and apoptotic index (AI) were observed in the subcutaneous transplant mouse model.
The growth-inhibiting rates in the WCAD-treated and 5-FU-treated groups of orthotopic transplant mouse model were 40.82% and 37.92% respectively whereas those of subcutaneous transplant mouse model were 48.70% and 60.10%. The incidence rates of metastasis in perigastric lymph notes, lymph nodes in the porta hepatis, liver, diaphragm and peritoneum in the WCAD-treated and 5-FU-treated groups were lower than those in the untreated control group, and the total metastasis rates in the WCAD-treated, 5-FU-treated and the untreated control groups were 30.77%, 28.57% and 71.43% respectively with significant differences (P<0.05). The total PCNA-positive rates in the WCAD-treated and 5-FU-treated groups were obviously lower than that in the untreated control group (P<0.05 or P<0.01) while the AI was higher than that in the untreated control group (P<0.01). The growth-inhibiting rate, total PCNA-positive rate and total metastasis rate in the WCAD-treated group had no significant differences as compared with those in the 5-FU-treated group, but the AI in the WCAD-treated group was significantly higher than that in the 5-FU-treated group (P<0.05).
WCAD has the inhibiting effects on tumor growth and metastasis of gastric cancer which is orthotopic implanted onto nude mice. This effect may be obtained by proliferation suppression and apoptosis induction in cancer.
评价胃肠安方对人胃癌原位移植裸鼠模型的抑瘤及抗转移作用。
41只裸鼠原位植入SGC-7901细胞，25只裸鼠皮下植入SGC-7901细胞。然后将各移植模型中的裸鼠分为相同的三组，即胃肠安方治疗组，每日口服胃肠安方0.5 ml；5-氟尿嘧啶治疗组，每周腹腔注射5-氟尿嘧啶50 mg/kg；未治疗对照组，每日口服生理盐水0.5 ml。检测原位移植小鼠模型中移植瘤的抑瘤率，检查转移灶，同时观察皮下移植小鼠模型中的增殖细胞核抗原（PCNA）阳性率和凋亡指数（AI）。
原位移植小鼠模型中胃肠安方治疗组和5-氟尿嘧啶治疗组的抑瘤率分别为40.82%和37.92%，皮下移植小鼠模型的抑瘤率分别为48.70%和60.10%。胃肠安方治疗组和5-氟尿嘧啶治疗组胃周淋巴结、肝门淋巴结、肝脏、膈肌和腹膜的转移发生率低于未治疗对照组，胃肠安方治疗组、5-氟尿嘧啶治疗组和未治疗对照组的总转移率分别为30.77%、28.57%和71.43%，差异有统计学意义（P<0.05）。胃肠安方治疗组和5-氟尿嘧啶治疗组的总PCNA阳性率明显低于未治疗对照组（P<0.05或P<0.01），而AI高于未治疗对照组（P<0.01）。胃肠安方治疗组的抑瘤率、总PCNA阳性率和总转移率与5-氟尿嘧啶治疗组相比无显著差异，但胃肠安方治疗组的AI明显高于5-氟尿嘧啶治疗组（P<0.05）。
胃肠安方对裸鼠原位移植的胃癌肿瘤生长和转移有抑制作用。这种作用可能是通过抑制肿瘤增殖和诱导肿瘤细胞凋亡来实现的。
